Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice

Biochemical and Biophysical Research Communications

Volumn 402, Issue 2, 2010, Pages 312-318

  Yamada, Marina ^a,b   Kida, Kotaro ^a   Amutuhaire, Willington ^a   Ichinose, Fumito ^a   Kaneki, Masao ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Apoptosis; Caspase 3; MPTP; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; BRADYKINESIA; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DISRUPTION; MALE; MICROGLIA; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; CASPASE 3; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE SILENCING; HYPOKINESIA; MALE; MICE; MICE, INBRED C57BL; NEUROTOXINS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS; PARKINSONIA; RODENTIA;

EID: 78149468522     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.023     Document Type: Article

References (40)

1. Alves G., Forsaa E.B., Pedersen K.F., Dreetz Gjerstad M., Larsen J.P. Epidemiology of Parkinson's disease. J. Neurol. 2008, 255(Suppl. 5):18-32.
2. Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 2003, 18:121-129.
3. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2875-2880.
4. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000, 166:29-43.
5. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Transm. 2000, 107:1-29.
6. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 1996, 137:120-123.
7. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 1998, 44:S142-S148.
8. Mochizuki H., Mori H., Mizuno Y. Apoptosis in neurodegenerative disorders. J. Neural Transm. 1997, Suppl. 50:125-140.
9. Kingsbury A.E., Mardsen C.D., Foster O.J. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?. Mov. Disord. 1998, 13:877-884.
10. Wullner U., Kornhuber J., Weller M., Schulz J.B., Loschmann P.A., Riederer P., Klockgether T. Cell death and apoptosis regulating proteins in Parkinson's disease-a cautionary note. Acta Neuropathol. 1999, 97:408-412.
11. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 1983, 80:4546-4550.
12. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
13. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation bid cleavage in 1-methyl-4-phenyl-1,3,2,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 2001, 21:9519-9528.
14. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., Ruberg M., Agid Y., Hirsch E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease but pathway inhibition results in neuronal necrosis. J. Neurosci. 2001, 21:2247-2255.
15. Turmel H., Hartmann A., Parain K., Douhou A., Srinivasan A., Agid Y., Hirsch E.C. Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov. Disord. 2001, 16:185-189.
16. Hassouna I., Wickert H., Zimmermann M., Gillardon F. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci. Lett. 1996, 204:85-88.
17. Serra P.A., Sciola L., Delogu M.R., Spano A., Monaco G., Miele E., Rocchitta G., Miele M., Migheli R., Desole M.S. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J. Biol. Chem. 2002, 277:34451-34461.
18. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-12,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
19. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2001, 98:2837-2842.
20. Novikova L., Garris B.L., Garris D.R., Lau Y.S. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience 2006, 140:67-76.
21. Spooren W.P., Gentsch C., Wiessner C. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1998, 85:649-651. discussion 653.
22. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 2004, 24:1865-1872.
23. Yang L., Sugama S., Mischak R.P., Kiaei M., Bizat N., Brouillet E., Joh T.H., Beal M.F. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP malonate and 3NP in vivo. Neurobiol. Dis. 2004, 17:250-259.
24. Dodel R.C., Du Y., Bales K.R., Ling Z.D., Carvey P.M., Paul S.M. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience 1998, 86:701-707.
25. Kaul S., Kanthasamy A., Kitazawa M., Anantharam V., Kanthasamy A.G. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur. J. Neurosci. 2003, 18:1387-1401.
26. Gomez C., Reiriz J., Pique M., Gil J., Ferrer I., Ambrosio S. Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 2001, 63:421-428.
27. Choi W.S., Yoon S.Y., Oh T.H., Choi E.J., O'Malley K.L., Oh Y.J. Two distinct mechanisms are involved in 6-hydroxydopamine-MPP+induced dopaminergic neuronal cell death: role of caspases ROS and JNK. J. Neurosci. Res. 1999, 57:86-94.
28. Han B.S., Hong H.S., Choi W.S., Markelonis G.J., Oh T.H., Oh Y.J. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J. Neurosci. 2003, 23:5069-5078.
29. Chu C.T., Zhu J.H., Cao G., Signore A., Wang S., Chen J. Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells. J. Neurochem. 2005, 94:1685-1695.
30. Woo M., Hakem R., Soengas M.S., Duncan G.S., Shahinian A., Kagi D., Hakem A., McCurrach M., Khoo W., Kaufman S.A., Senaldi G., Howard T., Lowe S.W., Mak T.W. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes. Dev. 1998, 12:806-819.
31. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
32. Chiba T., Yamada M., Sasabe J., Terashita K., Shimoda M., Matsuoka M., Aiso S. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol. Psychiatry 2009, 14:206-222.
33. Oki C., Watanabe Y., Yokoyama H., Shimoda T., Kato H., Araki T. Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell. Mol. Neurobiol. 2008, 28:417-430.
34. L. Frau, F. Borsini, J. Wardas, A.S. Khairnar, N. Schintu, M. Morelli, Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease, Synapse, (2010).
35. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
36. Shinozaki S., Inoue Y., Yang W., Fukaya M., Carter E.A., Ming-Yu Y., Fischman A., Tompkins R., Kaneki M. Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem. Biophys. Res. Commun. 2009, 391:1459-1464.
37. Mori A., Ohashi S., Nakai M., Moriizumi T., Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci. Res. 2005, 51:265-274.
38. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
39. Teismann P., Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes microglia and inflammation. Cell Tissue Res. 2004, 318:149-161.
40. Eberhardt O., Coelln R.V., Kugler S., Lindenau J., Rathke-Hartlieb S., Gerhardt E., Haid S., Isenmann S., Gravel C., Srinivasan A., Bahr M., Weller M., Dichgans J., Schulz J.B. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 2000, 20:9126-9134.